Stock Scorecard
Stock Summary for Integra Lifesciences Holdings Corp (IART) - $16.02 as of 10/24/2025 7:47:34 PM EST
Total Score
7 out of 30
Safety Score
38 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for IART
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for IART
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for IART
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for IART
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for IART (38 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 2 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for IART
Financial Details for IART
Company Overview |
|
|---|---|
| Ticker | IART |
| Company Name | Integra Lifesciences Holdings Corp |
| Country | USA |
| Description | Integra LifeSciences Holdings Corporation is a prominent global medical technology firm that specializes in the development and manufacture of innovative surgical implants and medical instruments for a range of applications, including neurosurgery, limb reconstruction, orthopedics, and general surgery. Based in Princeton, New Jersey, Integra is dedicated to improving patient outcomes through cutting-edge products that harness proprietary technologies and advanced research capabilities. With a strategic focus on addressing unmet medical needs, the company is well-positioned to capitalize on growth opportunities within the dynamic healthcare industry. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/29/2025 |
Stock Price History |
|
| Last Day Price | 16.02 |
| Price 4 Years Ago | 66.99 |
| Last Day Price Updated | 10/24/2025 7:47:34 PM EST |
| Last Day Volume | 965,585 |
| Average Daily Volume | 1,003,465 |
| 52-Week High | 27.13 |
| 52-Week Low | 11.06 |
| Last Price to 52 Week Low | 44.85% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 45.61 |
| Sector PE | 41.12 |
| 5-Year Average PE | 36.19 |
| Free Cash Flow Ratio | 5.72 |
| Industry Free Cash Flow Ratio | 39.17 |
| Sector Free Cash Flow Ratio | 31.25 |
| Current Ratio Most Recent Quarter | 1.23 |
| Total Cash Per Share | 2.80 |
| Book Value Per Share Most Recent Quarter | 13.33 |
| Price to Book Ratio | 1.05 |
| Industry Price to Book Ratio | 3.99 |
| Sector Price to Book Ratio | 32.29 |
| Price to Sales Ratio Twelve Trailing Months | 0.76 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.52 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.43 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 77,911,000 |
| Market Capitalization | 1,248,134,220 |
| Institutional Ownership | 94.37% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.46% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.40% |
| Annual Earnings Growth | -110.25% |
| Reported EPS 12 Trailing Months | -6.54 |
| Reported EPS Past Year | 0.12 |
| Reported EPS Prior Year | 2.56 |
| Net Income Twelve Trailing Months | -500,626,000 |
| Net Income Past Year | -6,944,000 |
| Net Income Prior Year | 67,741,000 |
| Quarterly Revenue Growth YOY | -0.60% |
| 5-Year Revenue Growth | 1.20% |
| Operating Margin Twelve Trailing Months | 7.86% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 217,914,000 |
| Total Cash Past Year | 246,375,000 |
| Total Cash Prior Year | 276,402,000 |
| Net Cash Position Most Recent Quarter | -1,009,028,000 |
| Net Cash Position Past Year | -949,642,000 |
| Long Term Debt Past Year | 1,196,017,000 |
| Long Term Debt Prior Year | 1,485,018,000 |
| Total Debt Most Recent Quarter | 1,226,942,000 |
| Equity to Debt Ratio Past Year | 0.56 |
| Equity to Debt Ratio Most Recent Quarter | 0.46 |
| Total Stockholder Equity Past Year | 1,545,280,000 |
| Total Stockholder Equity Prior Year | 1,587,884,000 |
| Total Stockholder Equity Most Recent Quarter | 1,038,661,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -58,635,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.75 |
| Free Cash Flow Past Year | 24,964,000 |
| Free Cash Flow Prior Year | 73,090,000 |
Options |
|
| Put/Call Ratio | 0.50 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.15 |
| MACD Signal | -0.01 |
| 20-Day Bollinger Lower Band | 10.89 |
| 20-Day Bollinger Middle Band | 13.67 |
| 20-Day Bollinger Upper Band | 16.44 |
| Beta | 1.21 |
| RSI | 61.74 |
| 50-Day SMA | 17.98 |
| 150-Day SMA | 32.22 |
| 200-Day SMA | 38.48 |
System |
|
| Modified | 10/23/2025 1:44:24 AM EST |